ABSTRACT: Pramlintide, a synthetic analog of amylin, improves postprandial hyperglycemia. We compared subcutaneous (s.c.) pramlintide injection with square wave pramlintide infusion in adolescents with type 1 diabetes (T1DM). Eight subjects with T1DM underwent two randomized studies. Subcutaneous pramlintide (dose ϭ 5 g/unit of insulin) bolus, was given one time and another time, the same dose was given as a 120-min s.c. infusion. Insulin dose was constant between studies. Gastric emptying was assessed with oral acetaminophen and [l- 
glycemia despite the use of insulin pump therapy and a good hemoglobin A1C (hemoglobin A 1c [HbA 1c ]) (9) . Postprandial glucose excursions failed to normalize despite a 60% increase in the premeal insulin bolus. Adjunctive use of pramlintide acetate with insulin effectively decreased immediate postprandial hyperglycemia. However, five of the eight subjects studied had immediate postprandial hypoglycemia, which was treated using small amounts of intravenous (i.v.) glucose. If delayed gastric emptying is the predominant effect of pramlintide action, then pramlintide injection may result in decreased carbohydrate absorption during peak pramlintide concentration. Postprandial hyperglycemia was also noted in the late postprandial period, indicating that there may be sudden glucagon or gastric content release resulting in this paradoxical glucose excursion. Previously, Kong et al. (10) demonstrated profound suppression of both solid and liquid phase of gastric emptying with i.v. pramlintide infusion . Hence, we hypothesized that pramlintide bolus injection will result in acute suppression of glucagon and gastric emptying that increases the risk of postprandial hypoglycemia while in the late postprandial period the sudden release of gastric content and or glucagon escape results in late postprandial hyperglycemia. The current study was undertaken to examine the role of administering pramlintide acetate either as a s.c. infusion over a 2-h period versus giving the same dose as a bolus injection before a mixed meal in T1DM and its effect on postmeal glucose excursions. Furthermore, we have characterized the effect of pramlintide on gastric emptying and glucagon. To our knowledge, this is the first study comparing pramlintide infusion to s.c. injection. Furthermore, this is the second report of pramlintide administration in pediatric T1DM.
METHODS
The Institutional Review Board of Baylor College of Medicine approved this investigator-initiated study. Amylin Pharmaceuticals, Inc. played no role in the design, implementation, or interpretation of these data. Informed consent was obtained in accordance with federal and institutional guidelines before entry into this trial.
Subjects. From our population of 1200 patients with T1DM, we approached patients aged 12-18 y who were on s.c. insulin pump therapy. Subjects had normal body mass index (BMI) (Ͻ90th percentile for age) and Hb Ն12 g/dL and were in moderate glycemic control with HbA 1c Յ8.5%. They had no other chronic conditions besides diabetes with or without hypothyroidism and were on no medications that affect glucose concentrations (except insulin). Subjects had a normal physical examination and were Tanner staged.
Pregnant and lactating females were excluded from the study. A total of nine subjects with T1DM were screened. Eight subjects with T1DM completed both studies. The clinical characteristics are shown in Table 1 . One subject opted out after receiving pramlintide infusion. The subject experienced nausea and vomiting associated with pramlintide administration and i.v. access problems. Control subjects did not have any side effects.
Study design. Subjects with T1DM underwent two studies in random order. On one occasion, subjects received pramlintide as a bolus injection just before the meal; on the other occasion (4 -6 wk apart), the same subjects received pramlintide as an s.c. infusion of the same dose of pramlintide. Data were also compared with our previous report wherein 11 T1DM subjects underwent a study identical in every respect to the current protocol with the exception that subjects did not receive pramlintide. Data on gastric emptying were not collected in the control experiment, and only data on eight subjects were previously reported (9) . The time between the control studies and pramlintide study was 8 mo to 1 y.
On the day before the study, subjects were admitted to the General Clinical Research Center (GCRC) for overnight management of their blood glucose concentrations. Subjects were on an insulin pump with short-acting insulin analogs: lispro or aspart. Usual insulin doses were administered with a standard dinner (composed of 60 -80 g of carbohydrate, and the macronutrient composition was 60% carbohydrates, 20% protein, and 20% fat) and bedtime snack (30 g of carbohydrate and a similar macronutrient composition as the dinner). The meal amounts were matched between all three studies. At 2200 h, an indwelling i.v. line was started in one of the antecubital veins to draw blood and administer glucose in the event of hypoglycemia. Reflectance meter blood glucoses were done every 60 min from 2200 to 0300 and every 30 min from 0300 to 0800. Blood glucose was maintained between 5 and 7.2 mM by varying the rate of s.c. continuous insulin infusion. Hypoglycemia was avoided by giving 2-7 g of i.v. glucose if the blood glucose was Ͻ4.4 mM.
On the morning of the study, a second indwelling line was placed in the contralateral antecubital space or forearm/hand vein as back-up access in the event of hypoglycemia. Baseline blood samples of glucose, insulin, pramlintide, and glucagon were drawn before study start. The subjects then received an insulin bolus just before test meal, which was based on a standard meal and their usual insulin-to-carbohydrate ratio. Insulin was given as a bolus via an insulin pump. Pramlintide was calculated based on the insulin dose (5 g of pramlintide/unit of insulin). Pramlintide was given either as an s.c. bolus using a separate syringe or as a square wave bolus over a 120-min period by an s.c. infusion pump. The dose of pramlintide was identical in both studies. At time 0, subjects drank a standard liquid meal of Boost High Protein Drink 12 oz (360 calories, 50 g of carbohydrate, 9 g of fat, and 22 g of protein) over a period of 10 min. The liquid meal was enriched with 1 g of [l-
13 C]glucose, and breath samples for 13 CO 2 analysis were collected in two tubes at 17 time points during the study. In addition to [ 13 C]glucose measurements, acetaminophen was given 20 mg/kg orally as a marker for gastric emptying. Blood samples for insulin and glucagon were drawn at 10-to 30-min intervals for 300 min. Blood glucose was measured at the bedside using a glucose analyzer (YSI 2300 Stat Plus, Yellow Springs Instruments Company Inc., Yellow Springs, OH) at 10-min intervals from Ϫ60 min to 300 min. Blood samples were obtained before pramlintide dosing and at 20, 40, 60, 120, 180, 240, and 300 min following drug administration. Acetaminophen sampling was done at the following time points: Ϫ10, 30, 60, 100, 180, and 300 min. Following collection, samples were immediately centrifuged at 5000 ϫ g for 5 min and stored at ՅϪ20°C until analysis. During the study, if the subject's blood glucose values were Ͻ3 mM, i.v. glucose (5-7 g) was given to correct low blood glucose.
Control study. Eleven control subjects with T1DM (previously reported study) who received only insulin and no pramlintide were compared with subjects who received pramlintide either as an infusion or injection in addition to insulin. The study protocols were identical except that in the control study, data on gastric emptying were not obtained.
Measurements. Blood glucose concentrations were measured using a glucose analyzer (YSI 2300 Stat Plus, Yellow Springs Instruments Company Inc.). The DCA 2000 Hb A1C System (Bayer, Elkhart, IN) was used for measuring the percentage concentration of HbA 1c in the blood. The assay is based on a latex immunoagglutination inhibition method. Both the concentration of HbA 1c specifically and the concentration of total Hb are measured, and the ratio reported as percent HbA 1c . HbA 1c concentration in the range of 2.5% to Ͼ14.0% is reported.
An ultrasensitive radioimmunoassay determines ultrafiltrate insulin with a detection limit of 0.5 U/mL. Glucagon was measured using an immunoassay specific to pancreatic glucagon with 4.5% intra-assay variability and a 7.1% interassay variability. All kits used were purchased from Linco Research Inc. Plasma pramlintide concentrations were measured by Amylin Pharmaceuticals, Inc., using a validated two site-specific immunoradiometric assay (11). 13 CO 2 was measured in breath samples using an isotopic mass spectrometer (Thermo-Finnigan Gas Bench-II coupled with Finnigan Delta ϩ XL IRMS). The expired 13 CO 2 after test drink ingestion of the oral liquid meal was compared with the baseline value, and results were expressed as an absolute increase in 13 C in ␦% (12). MDS Pharma Services using a high-performance liquid chromatography methodology assayed acetaminophen.
Statistics. Repeated-measures analysis of variance (ANOVA) was used to analyze glucose and hormonal excursions. Paired comparisons were made for pramlintide studies and unpaired comparisons were made for control study to pramlintide administration. Significance was considered at a 0.05 level, post hoc analysis using a paired two-tailed t test was applied. GraphPad Prism 4.0 was used for data analysis. Area under the curve (AUC) was analyzed using the trapezoidal rule using Excel version 7.0. Figure 1 depicts the plasma concentrations of glucose and insulin before and after a meal in T1DM subjects with and without pramlintide use. In the control study, when subjects received only insulin, glucose excursions were increased and remained higher for an extended period of time compared with adjunctive pramlintide infusion. However, pramlintide injection resulted in immedi- Figure 2 demonstrates that glucagon concentrations were suppressed in response to a bolus injection compared with an infusion (p Ͻ 0.0003). Gastric emptying as measured by 13 CO 2 in breath and acetaminophen concentrations were significantly suppressed when pramlintide was given as a bolus injection compared with infusion. The changes in gastric emptying and glucagon suppression occurred during peak pramlintide action after the injection. Adverse events. All subjects had lowering of blood glucose after pramlintide injection in the range of 3.3-3.8 mM. Two subjects who received pramlintide injection experienced hypoglycemia after the meal and required additional i.v. glucose per protocol. One subject had a nadir of 2.2 mM at 90 min and one subject had a nadir of 2.64 at 80 min. One subject who received pramlintide infusion had nausea and vomiting.
RESULTS

Glucose and insulin concentrations.
DISCUSSION
This study investigates the role of pramlintide acetate given as an s.c. infusion rather than a bolus injection. These data demonstrate that pramlintide acetate causes an acute reduction in glucose concentrations when given as a bolus injection. Greater delay in gastric emptying and glucagon suppression was noted when pramlintide acetate injection was administered as a bolus rather than an infusion, and these effects coincided with lower blood glucose concentrations.
Previously, we showed that five of eight subjects had immediate postprandial hypoglycemia and four received i.v. glucose to treat low blood glucose. In this study, lowering of prandial pramlintide bolus dose and using pramlintide as a function of insulin resulted in decreased glycemic excursions. However, despite these changes, two patients required i.v. glucose as per protocol when pramlintide bolus injection resulted in immediate postprandial hypoglycemia. The insulin-to-pramlintide ratio used in our study will decrease the incidence of postprandial hypoglycemia, and in the clinical setting, this ratio can be individualized and daily activities and exercise be taken in to consideration. Decreasing insulin doses can also diminish this risk of hypoglycemia (13) . In our study, we did not change insulin dose but changed the mode of delivery of pramlintide to a square wave s.c. infusion to determine whether the intervention would alter glucose excursions. A combination of changes may be required in the clinical setting to eliminate the risk of immediate postprandial hypoglycemia (14) .
Both gastric emptying and glucagon suppression occur as a result of pramlintide administration. However, this suppression is more profound with the injection compared with the infusion. One of the limitations of our study is that we were unable to compare glucagon and gastric modulation in control patients who did not receive pramlintide. Modulation of gastric emptying as a means of decreasing postprandial hyperglycemia has been previously examined. The alphaglucosidase inhibitors, such as acarbose and miglitol, delay gastric emptying and decrease postprandial hyperglycemia (15) by modulating delivery of carbohydrates to the gut. However, their use is limited due to their side effects (16) . Intravenous pramlintide profoundly slows gastric emptying (10) ; hence, in our study, we use pramlintide subcutaneously. We used two measures for gastric emptying because we wanted to substantiate it by two different methods. In addition, [l- 13 C]glucose will allow us in the future to examine gastric emptying in children in a noninvasive way with no additional blood samples. Currently, we are examining the role of using two pumps: one for insulin and the other for adjunctive pramlintide to determine the dose that may be required during pre-and the postprandial periods to prevent postprandial hyperglycemia and late preprandial hypoglycemia.
Timing of pramlintide delivery has been previously examined by Weyer et al. (17) , and they found that giving pramlintide before meal was the only way to decrease immediate postprandial hyperglycemia. Hence, our study used pramlintide before meal, but it may be that a much higher dose of pramlintide is required right at the start of the meal to prevent immediate postprandial hyperglycemia, which did not occur with using a square wave bolus. A different type of bolus such as a dual wave bolus may yield more favorable glucose results, and studies to examine that question are currently being done in our laboratory.
The role of preventing hypoglycemia with the use of glucagon has been investigated by many studies (9,18 -20) . However, the use of pramlintide may obviate the need to use exogenous glucagon, and endogenous glucagon modulation may decrease both late postprandial hypoglycemia and suppression of glucagon may decrease immediate postprandial hyperglycemia (21) . Pramlintide in addition to hypoglycemia can result in nausea. However, compared with our earlier report (9) , only one subject suffered from nausea. The lowered pramlintide dose may have resulted in the decreased incidence of nausea in this study. This is an improvement from our earlier report wherein there were two subjects who had nausea and one subject who had vomiting. In long-term studies, nausea can occur in the first weeks of initiation of treatment (13, 22) . Although the exact mechanism of this side effect is not known, amylin binds to the area postrema, which is colocated with the chemoreceptor trigger zone resulting in nausea and/or vomiting. Commencing pramlintide at a low dose, especially in the first week, may lower the risk of nausea, and further studies in refining the insulin-topramlintide ratio would allow physicians flexible dosing.
In summary, our results suggest that modulating gastric emptying and/or glucagon suppression occurs with the use of adjunctive pramlintide in the treatment of T1DM patients. Pramlintide injection can decrease immediate postprandial hyperglycemia and should be used with caution with appropriate information to patients regarding risk of hypoglycemia. More studies are needed to determine whether continuous s.c. pramlintide infusion has a role in preventing postprandial hyperglycemia and preventing meal pramlintide injection related hypoglycemia. Ongoing studies in our laboratory using variations of boluses such as dual wave and regular wave are currently under way. These studies will allow us in the future to use pramlintide in a safe and effective way in patients with T1DM.
